As of November 14, 2026, Protagenic Therapeutics, Inc.\new has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 3, 2026 to April 7, 2026 (Form 8-K, April 7, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Protagenic Therapeutics, Inc.\new? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Protagenic Therapeutics, Inc.\new reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-03 to 2026-04-07. Every row below is cited to the filing it comes from, and this page adds each new change as Protagenic Therapeutics, Inc.\new files it.
Also on the record for Protagenic Therapeutics, Inc.\new
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 25, 2025 | Stake report, Schedule 13G/A, by BIGGER CAPITAL FUND L P | — | 5%+ stakes | Source |
| July 8, 2025 | Stake report, Schedule 13G, by BIGGER CAPITAL FUND L P | 5.75% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Protagenic Therapeutics, Inc.\new now and the warning signs.
Free to see. No signup.
Keep reading
More on Protagenic Therapeutics, Inc.\new and the records around it.
Companies that share a holder
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: Neuraxis, INC (Nov 2026), ClearPoint Neuro, Inc. (Nov 2026), Dermata Therapeutics, Inc. (Nov 2026)
Watch Protagenic Therapeutics, Inc.\new
Get an email when Protagenic Therapeutics, Inc.\new files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Protagenic Therapeutics, Inc.\new?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Protagenic Therapeutics, Inc.\new: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Protagenic Therapeutics, Inc.\new covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-07 | Reported | not named in the filing | 8-K, 2026-04-07 | ||
| 2026-03-03 | Reported | not named in the filing | 8-K, 2026-03-03 |
New leaders reset buying decisions — get the Full Report on Protagenic Therapeutics, Inc.\new: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Protagenic Therapeutics, Inc.\new, with the record behind each one.
Find candidates like senior executive at Protagenic Therapeutics, Inc.\newEvery change, in the filing's words
Reported
On March 31, 2026, the Board of Directors of Protagenic Therapeutics, Inc. (the "Company") notified Alexander Arrow, MD, the Company's Chief Financial Officer, that his employment with the Company will be terminated effective April 30, 2026.
Reported
On February 3, 2026, the Board of Directors (the "Board") of Protagenic Therapeutics, Inc. (the "Company") appointed William (Bill) Nichols, Jr., age 51, as President of the Company.
- During the past five years, Mr. Nichols has held senior commercial leadership roles at bluebird bio, a biotechnology company, and previously held senior commercial leadership roles at Dova Pharmaceuticals (now Sobi) and Bristol-Myers Squibb, each a biopharmaceutical company.
- Under the terms of his employment agreement, Mr. Nichols will receive an annual base salary of $350,000 and will be eligible for an annual target bonus equal to 40% of his base salary.
- The employment agreement also contemplates an option grant equal to approximately 1.0% of the Company's fully diluted share count.
Tools for this story
Each opens in a new tab, filled in for Protagenic Therapeutics, Inc.\new. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
